---
document_datetime: 2025-11-23 08:05:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-biopartners.html
document_name: ribavirin-biopartners.html
version: success
processing_time: 0.0997607
conversion_datetime: 2025-12-26 13:01:34.12747
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ribavirin BioPartners

[RSS](/en/individual-human-medicine.xml/66290)

##### Lapsed

This medicine's authorisation has lapsed

ribavirin

Medicine

Human

Lapsed

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 09 April 2010, the European Commission (EC) issued a marketing authorisation valid throughout the European Union (EU) for the medicinal product Ribavirin BioPartners (ribavirin), indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents.

The Marketing Authorisation Holder (MAH) responsible for Ribavirin BioPartners was BioPartners GmbH. Ribavirin BioPartners has not been marketed anywhere in the EU since the granting of the marketing authorisation. As the product has not been marketed for three consecutive years, in accordance with Article 14(4) of Regulation (EC) N° 726/2004 (\"Sunset Clause\"), the marketing authorisation of Ribavirin BioPartners has ceased to be valid. BioPartners GmbH was notified accordingly by letter dated 09 April 2013.

The European Public Assessment Report for Ribavirin BioPartners is updated to reflect that the marketing authorisation is no longer valid.

Ribavirin BioPartners : EPAR - Summary for the public

English (EN) (174.37 KB - PDF)

**First published:** 26/04/2010

**Last updated:** 06/05/2013

[View](/en/documents/overview/ribavirin-biopartners-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-30)

български (BG) (271.53 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/bg/documents/overview/ribavirin-biopartners-epar-summary-public_bg.pdf)

español (ES) (236.46 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/es/documents/overview/ribavirin-biopartners-epar-summary-public_es.pdf)

čeština (CS) (261.14 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/cs/documents/overview/ribavirin-biopartners-epar-summary-public_cs.pdf)

dansk (DA) (235.91 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/da/documents/overview/ribavirin-biopartners-epar-summary-public_da.pdf)

Deutsch (DE) (237.45 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/de/documents/overview/ribavirin-biopartners-epar-summary-public_de.pdf)

eesti keel (ET) (236.46 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/et/documents/overview/ribavirin-biopartners-epar-summary-public_et.pdf)

ελληνικά (EL) (276.72 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/el/documents/overview/ribavirin-biopartners-epar-summary-public_el.pdf)

français (FR) (236.13 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fr/documents/overview/ribavirin-biopartners-epar-summary-public_fr.pdf)

italiano (IT) (237.43 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/it/documents/overview/ribavirin-biopartners-epar-summary-public_it.pdf)

latviešu valoda (LV) (261.29 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lv/documents/overview/ribavirin-biopartners-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (259.26 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lt/documents/overview/ribavirin-biopartners-epar-summary-public_lt.pdf)

magyar (HU) (258.14 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/hu/documents/overview/ribavirin-biopartners-epar-summary-public_hu.pdf)

Malti (MT) (200.9 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/mt/documents/overview/ribavirin-biopartners-epar-summary-public_mt.pdf)

Nederlands (NL) (235.99 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/nl/documents/overview/ribavirin-biopartners-epar-summary-public_nl.pdf)

polski (PL) (264.47 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pl/documents/overview/ribavirin-biopartners-epar-summary-public_pl.pdf)

português (PT) (237.54 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pt/documents/overview/ribavirin-biopartners-epar-summary-public_pt.pdf)

română (RO) (259.37 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/ro/documents/overview/ribavirin-biopartners-epar-summary-public_ro.pdf)

slovenčina (SK) (259.97 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sk/documents/overview/ribavirin-biopartners-epar-summary-public_sk.pdf)

slovenščina (SL) (257.06 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sl/documents/overview/ribavirin-biopartners-epar-summary-public_sl.pdf)

Suomi (FI) (235.93 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fi/documents/overview/ribavirin-biopartners-epar-summary-public_fi.pdf)

svenska (SV) (235.69 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sv/documents/overview/ribavirin-biopartners-epar-summary-public_sv.pdf)

## Product information

Ribavirin BioPartners : EPAR - Product Information

English (EN) (337.61 KB - PDF)

**First published:** 26/04/2010

**Last updated:** 06/05/2013

[View](/en/documents/product-information/ribavirin-biopartners-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-650)

български (BG) (670.28 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/bg/documents/product-information/ribavirin-biopartners-epar-product-information_bg.pdf)

español (ES) (381.52 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/es/documents/product-information/ribavirin-biopartners-epar-product-information_es.pdf)

čeština (CS) (455.28 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/cs/documents/product-information/ribavirin-biopartners-epar-product-information_cs.pdf)

dansk (DA) (358.92 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/da/documents/product-information/ribavirin-biopartners-epar-product-information_da.pdf)

Deutsch (DE) (382.04 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/de/documents/product-information/ribavirin-biopartners-epar-product-information_de.pdf)

eesti keel (ET) (370.67 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/et/documents/product-information/ribavirin-biopartners-epar-product-information_et.pdf)

ελληνικά (EL) (690.3 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/el/documents/product-information/ribavirin-biopartners-epar-product-information_el.pdf)

français (FR) (389.46 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fr/documents/product-information/ribavirin-biopartners-epar-product-information_fr.pdf)

íslenska (IS) (346.67 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/is/documents/product-information/ribavirin-biopartners-epar-product-information_is.pdf)

italiano (IT) (371.1 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/it/documents/product-information/ribavirin-biopartners-epar-product-information_it.pdf)

latviešu valoda (LV) (489.48 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lv/documents/product-information/ribavirin-biopartners-epar-product-information_lv.pdf)

lietuvių kalba (LT) (442.65 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lt/documents/product-information/ribavirin-biopartners-epar-product-information_lt.pdf)

magyar (HU) (475.05 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/hu/documents/product-information/ribavirin-biopartners-epar-product-information_hu.pdf)

Malti (MT) (441.92 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/mt/documents/product-information/ribavirin-biopartners-epar-product-information_mt.pdf)

Nederlands (NL) (444.86 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/nl/documents/product-information/ribavirin-biopartners-epar-product-information_nl.pdf)

norsk (NO) (355.1 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/no/documents/product-information/ribavirin-biopartners-epar-product-information_no.pdf)

polski (PL) (492.51 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pl/documents/product-information/ribavirin-biopartners-epar-product-information_pl.pdf)

português (PT) (380.51 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pt/documents/product-information/ribavirin-biopartners-epar-product-information_pt.pdf)

română (RO) (455.65 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/ro/documents/product-information/ribavirin-biopartners-epar-product-information_ro.pdf)

slovenčina (SK) (434.61 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sk/documents/product-information/ribavirin-biopartners-epar-product-information_sk.pdf)

slovenščina (SL) (405.45 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sl/documents/product-information/ribavirin-biopartners-epar-product-information_sl.pdf)

Suomi (FI) (428.93 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fi/documents/product-information/ribavirin-biopartners-epar-product-information_fi.pdf)

svenska (SV) (367.82 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sv/documents/product-information/ribavirin-biopartners-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0003/G 21/11/2012

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ribavirin BioPartners : EPAR - All Authorised presentations

English (EN) (127.83 KB - PDF)

**First published:** 26/04/2010

**Last updated:** 06/05/2013

[View](/en/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-963)

български (BG) (196.95 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/bg/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_bg.pdf)

español (ES) (128.39 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/es/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_es.pdf)

čeština (CS) (157.27 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/cs/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (128.09 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/da/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (128 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/de/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (128.37 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/et/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (192.27 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/el/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_el.pdf)

français (FR) (128.31 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fr/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (127.9 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/it/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (193.19 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lv/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (194.22 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/lt/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (158.08 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/hu/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (192.65 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/mt/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (127.81 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/nl/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_nl.pdf)

polski (PL) (159.08 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pl/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_pl.pdf)

português (PT) (128.43 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/pt/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_pt.pdf)

română (RO) (191.07 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/ro/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (194.2 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sk/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (127.9 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sl/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (128.21 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/fi/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.44 KB - PDF)

**First published:**

26/04/2010

**Last updated:**

06/05/2013

[View](/sv/documents/all-authorised-presentations/ribavirin-biopartners-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ribavirin BioPartners Active substance ribavirin International non-proprietary name (INN) or common name ribavirin Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AB04

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).

**Naïve patients**

*Adult patients*

Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)

*Children three years of age and older and adolescents*

Ribavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.

When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).

**Previous-treatment-failure patients**

*Adult patients*

Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/001184

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

BioPartners GmbH

Kaiserpassage 11

Marketing authorisation issued 06/04/2010 Lapse of marketing authorisation 09/04/2013 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ribavirin BioPartners : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (282.13 KB - PDF)

**First published:** 13/12/2010

**Last updated:** 06/05/2013

[View](/en/documents/procedural-steps-after/ribavirin-biopartners-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ribavirin BioPartners : EPAR - Public assessment report

English (EN) (332.7 KB - PDF)

**First published:** 26/04/2010

**Last updated:** 06/05/2013

[View](/en/documents/assessment-report/ribavirin-biopartners-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ribavirin BioPartners

Adopted

Reference Number: EMA/CHMP/40892/2010

English (EN) (171.88 KB - PDF)

**First published:** 22/01/2010

**Last updated:** 06/05/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ribavirin-biopartners_en.pdf)

**This page was last updated on** 06/05/2013

## Share this page

[Back to top](#main-content)